1. Home
  2. ENTA
  3. ENTA News

Latest Enanta Pharmaceuticals Inc. (ENTA) News on October 9, 2025

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
ENTA

Business Wire

2 days ago

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

ENTA

MT Newswires

7 days ago

Enanta Pharmaceuticals Closes Stock Offering

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ENTA

Business Wire

7 days ago

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ENTA

MT Newswires

8 days ago

Jefferies Upgrades Enanta Pharmaceuticals to Buy From Hold, $20 Price Target

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
ENTA

Business Wire

3 months ago

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
ENTA

Business Wire

4 months ago

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
ENTA

Business Wire

4 months ago

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
ENTA

Business Wire

5 months ago

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
ENTA

Zacks

5 months ago

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ENTA

Simply Wall St.

5 months ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
ENTA

Zacks

5 months ago

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

ENTA

Associated Press Finance

5 months ago

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
ENTA

Business Wire

5 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
ENTA

Zacks

5 months ago

Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts
ENTA

Insider Monkey

5 months ago

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

ENTA

MT Newswires

5 months ago

Top Premarket Gainers

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
ENTA

Business Wire

6 months ago

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
ENTA

Business Wire

7 months ago

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
ENTA

Business Wire

7 months ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
ENTA

Simply Wall St.

8 months ago

With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns

President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
ENTA

Simply Wall St.

8 months ago

President of Enanta Pharmaceuticals Picks Up 5.9% More Stock

Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
ENTA

Zacks

8 months ago

Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade

ENTA

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 02/13/2025

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
ENTA

Zacks

8 months ago

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

ENTA

Associated Press Finance

8 months ago

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
ENTA

Business Wire

8 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
ENTA

Clinical Trials Arena

8 months ago

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
ENTA

Zacks

9 months ago

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ENTA

Business Wire

9 months ago

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ENTA

MT Newswires

9 months ago

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

ENTA

MT Newswires

9 months ago

Top Midday Decliners

ENTA

MT Newswires

10 months ago

Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer

ENTA

MT Newswires

10 months ago

HC Wainwright Adjusts Price Target on Enanta Pharmaceuticals to $18 From $27, Maintains Buy Rating

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
ENTA

Business Wire

10 months ago

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
ENTA

Zacks

10 months ago

Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial
ENTA

Clinical Trials Arena

10 months ago

Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial

ENTA

MT Newswires

10 months ago

Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
ENTA

Business Wire

10 months ago

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
ENTA

Business Wire

10 months ago

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
ENTA

TipRanks

10 months ago

Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility

ENTA

MT Newswires

10 months ago

Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating

ENTA

MT Newswires

10 months ago

Enanta Pharmaceuticals Fiscal Q4 Net Loss Widens, Revenue Declines

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
ENTA

Zacks

10 months ago

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates

ENTA

Associated Press Finance

10 months ago

Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
ENTA

Business Wire

10 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable
ENTA

Simply Wall St.

a year ago

The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable

Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline
ENTA

Insider Monkey

a year ago

Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline

Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares
ENTA

GuruFocus.com

a year ago

Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
ENTA

Zacks

a year ago

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
ENTA

BioPharma Dive

a year ago

J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers

ENTA

MT Newswires

a year ago

Enanta Pharmaceuticals Says Phase 2a Trial of Potential RSV Treatment Meets Endpoints

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Participate in Investor Conferences in September
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?
ENTA

Insider Monkey

a year ago

Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?

Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
ENTA

Simply Wall St.

a year ago

Enanta Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
ENTA

Zacks

a year ago

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

ENTA

Associated Press Finance

a year ago

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
ENTA

Zacks

a year ago

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ENTA

Simply Wall St.

a year ago

Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ENTA

MT Newswires

a year ago

JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
ENTA

Insider Monkey

a year ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript

ENTA

Thomson Reuters StreetEvents

a year ago

Q2 2024 Enanta Pharmaceuticals Inc Earnings Call

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

ENTA

GuruFocus.com

a year ago

Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...

Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations
ENTA

GuruFocus.com

a year ago

Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
ENTA

Zacks

a year ago

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

ENTA

Associated Press Finance

a year ago

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss
ENTA

Simply Wall St.

a year ago

Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
ENTA

Business Wire

a year ago

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
ENTA

Business Wire

2 years ago

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
ENTA

Simply Wall St.

2 years ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript
ENTA

Insider Monkey

2 years ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript

ENTA

Thomson Reuters StreetEvents

2 years ago

Q1 2024 Enanta Pharmaceuticals Inc Earnings Call

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
ENTA

Zacks

2 years ago

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ...
ENTA

GuruFocus.com

2 years ago

Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ...

ENTA

Associated Press Finance

2 years ago

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
ENTA

Business Wire

2 years ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
ENTA

Business Wire

2 years ago

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rainbow Realty Group Announces Launch of Fund IV: Capitalizing on a Moment in Time
ENTA

PR Newswire

2 years ago

Rainbow Realty Group Announces Launch of Fund IV: Capitalizing on a Moment in Time

ENTA

Reuters

2 years ago

UPDATE 2-Novavax announces fresh round of layoffs to rein in costs

Novavax announces fresh round of layoffs to rein in costs
ENTA

Reuters

2 years ago

Novavax announces fresh round of layoffs to rein in costs

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023
ENTA

Business Wire

2 years ago

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Fubo Makes Strategic Investment in BKFC, Will Stream BKFC 57 Live Event on February 2
ENTA

Business Wire

2 years ago

Fubo Makes Strategic Investment in BKFC, Will Stream BKFC 57 Live Event on February 2

Nukkleus Appoints C. Derek Campbell to Board of Directors, Bolstering its Growing Footprint in Emerging Markets
ENTA

Business Wire

2 years ago

Nukkleus Appoints C. Derek Campbell to Board of Directors, Bolstering its Growing Footprint in Emerging Markets

ENTA

Business Wire

2 years ago

ClearBridge MLP Funds Announce Proposed Mergers and Updates for Tender Offers

Earnings Preview: BrightSphere Investment Group (BSIG) Q4 Earnings Expected to Decline
ENTA

Zacks

2 years ago

Earnings Preview: BrightSphere Investment Group (BSIG) Q4 Earnings Expected to Decline

ENTA

Associated Press Finance

2 years ago

LSI: Fiscal Q2 Earnings Snapshot

LSI Industries Reports Fiscal 2024 Second Quarter Results and Declares Quarterly Cash Dividend
ENTA

Business Wire

2 years ago

LSI Industries Reports Fiscal 2024 Second Quarter Results and Declares Quarterly Cash Dividend

Citizens & Northern Corp's Dividend Analysis
ENTA

GuruFocus.com

2 years ago

Citizens & Northern Corp's Dividend Analysis

McEwen (MUX) Loses -13.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ENTA

Zacks

2 years ago

McEwen (MUX) Loses -13.83% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

National News Literacy Week 2024: Spotlight on local news
ENTA

PR Newswire

2 years ago

National News Literacy Week 2024: Spotlight on local news

ENTA

Business Wire

2 years ago

Franklin Templeton Fund Adviser, LLC Announces Distributions for the Month of February 2024

Compass Diversified Promises Faster Growth to Investors
ENTA

Barrons.com

2 years ago

Compass Diversified Promises Faster Growth to Investors

Getty Realty Corp. Announces 2023 Dividend Tax Treatment
ENTA

GlobeNewswire

2 years ago

Getty Realty Corp. Announces 2023 Dividend Tax Treatment

Share on Social Networks: